Skip to main content

Nexgel, Inc.

NXGL
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001468929

No open-market purchases or sales by Nexgel, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $293.0K in total; no superinvestor holds it.

Other share classesNXGLW

Key figures

Market capClose on Nov 17, 2026
$2.04M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +1 vs. previous quarter
19
13F valueReported value at the end of Q2 2026
$293.0K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$11.4M
+31.5% year over year
Net income, FY2025
-$3.00M
No comparable prior period
Free cash flow, FY2025
-$1.38M
No comparable prior period
Revenue, Q3 FY2026
$3.18M
+8.4% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $3.00M (26.3% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
24.0K
Shares sold short
Change
−80.7K
−77.0% vs. previous
Days to cover
1.00
At average daily volume

Superinvestors holding NXGL, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding NXGL at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Nexgel, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 13, 2026 (view filing)9:59 PM ETNov 103 daysKieser Brian JosephInterim CEOPPurchase+133.2K$5.50+$732.7KNew position133.2K afterPrice outlier
Nov 13, 2026 (view filing)9:59 PM ETNov 103 daysKieser Brian JosephInterim CEOPPurchase+133.2K$0.00$0–133.2K afterDerivative
Nov 13, 2026 (view filing)9:58 PM ETNov 103 daysglassman steven markDirectorPPurchase+4.55K$5.50+$25.0K+58.0%12.4K afterPrice outlier
Nov 13, 2026 (view filing)9:58 PM ETNov 103 daysglassman steven markDirectorPPurchase+4.55K$0.00$0–4.55K afterDerivative
Jun 23, 2026 (view filing)Jun 18-235 daysLevy Adam R.Chief Executive OfficerSSale−11.0K$0.59−$6.49K−3.3%322.7K after2 lots
Jun 15, 2026 (view filing)Jun 114 daysLevy Adam R.Chief Executive OfficerSSale−3.00K$0.61−$1.83K−0.9%333.7K after
Jun 9, 2026 (view filing)Jun 4-85 daysLateLevy Adam R.Chief Executive OfficerSSale−6.00K$0.57−$3.42K−1.8%336.7K after2 lots
Jun 3, 2026 (view filing)Jun 12 daysLevy Adam R.Chief Executive OfficerSSale−2.00K$0.59−$1.18K−0.6%342.7K after
May 29, 2026 (view filing)May 27-292 daysLevy Adam R.Chief Executive OfficerSSale−13.0K$0.6054−$7.87K−3.6%344.7K after3 lots
May 18, 2026 (view filing)May 144 daysHenry Scott RobertDirectorPPurchase+62.5K$0.40+$25.0K–20.8K afterDerivative2 lots

Top 10 13F holders, Q2 2026

See all 19 holders

The largest institutional positions in Nexgel, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding NXGL in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Susquehanna International Group, LLP85,140$42.7K0.00%+85,140New
Virtu Financial LLC79,128$40.0K0.00%+79,128New
Geode Capital Management, LLC71,863$36.0K0.00%−56,673−44.1%Reduced
HRT Financial LP69,485$34.0K0.00%+53,989+348.4%Added
Morgan Stanley54,980$27.5K0.00%00.0%Unchanged
Vanguard Capital Management LLC48,920$24.5K0.00%00.0%Unchanged
Citadel Advisors LLC40,976$20.5K0.00%+40,976New
Vanguard Fiduciary Trust Co34,040$17.1K0.00%00.0%Unchanged
UBS Group AG24,735$12.4K0.00%+18,101+272.9%Added
Jane Street Group, LLC20,606$10.3K0.00%−21,532−51.1%Reduced

Holders of 5% or more of NXGL

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Nexgel, Inc..

Largest holders of NXGL from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Asymmetry Point LP13G/A8.80%745.0K shares+1.31 ppfrom 7.49%Mar 12, 20262 filingsApr 29, 2026SEC